Experimental and new investigational drugs for the treatment of uterine fibroids
INTRODUCTION: Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss. Advancements in understanding fibroid pathophysiology have prompted the exploration of new compounds to overcome current therapy limitations.
AREAS COVERED: This manuscript offers an updated overview of investigational drugs for symptomatic uterine fibroids.
EXPERT OPINION: Despite ulipristal acetate's well-established efficacy as a selective progesterone receptor modulator (SPRM) in fibroid treatment, its prescription has declined due to the rare but severe risk of liver damage. Oral GnRH antagonists, like elagolix, relugolix, and linzagolix, with their novel pharmacodynamic properties, are gaining traction in fibroid management, inducing a dose-dependent reduction in circulating sex hormone levels. Ongoing research on natural compounds, such as vitamin D and epigallocatechin gallate (EGCG), presents emerging options for treating uterine fibroids. This evolving landscape reflects the ongoing efforts to improve therapeutic outcomes for individuals with symptomatic uterine fibroids.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - (2024) vom: 17. Apr., Seite 1-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Evangelisti, Giulio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Elagolix |
|---|
| Anmerkungen: |
Date Revised 17.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/13543784.2024.2343786 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371082595 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371082595 | ||
| 003 | DE-627 | ||
| 005 | 20240417233008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2024.2343786 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM371082595 | ||
| 035 | |a (NLM)38618931 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Evangelisti, Giulio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experimental and new investigational drugs for the treatment of uterine fibroids |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a INTRODUCTION: Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss. Advancements in understanding fibroid pathophysiology have prompted the exploration of new compounds to overcome current therapy limitations | ||
| 520 | |a AREAS COVERED: This manuscript offers an updated overview of investigational drugs for symptomatic uterine fibroids | ||
| 520 | |a EXPERT OPINION: Despite ulipristal acetate's well-established efficacy as a selective progesterone receptor modulator (SPRM) in fibroid treatment, its prescription has declined due to the rare but severe risk of liver damage. Oral GnRH antagonists, like elagolix, relugolix, and linzagolix, with their novel pharmacodynamic properties, are gaining traction in fibroid management, inducing a dose-dependent reduction in circulating sex hormone levels. Ongoing research on natural compounds, such as vitamin D and epigallocatechin gallate (EGCG), presents emerging options for treating uterine fibroids. This evolving landscape reflects the ongoing efforts to improve therapeutic outcomes for individuals with symptomatic uterine fibroids | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a GnRH-agonists | |
| 650 | 4 | |a Uterine fibroids | |
| 650 | 4 | |a elagolix | |
| 650 | 4 | |a epigallocatechin gallate | |
| 650 | 4 | |a linzagolix | |
| 650 | 4 | |a relugolix | |
| 650 | 4 | |a ulipristal acetate | |
| 650 | 4 | |a vitamin D | |
| 700 | 1 | |a Ferrero, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Perrone, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Gustavino, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Volpi, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Izzotti, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Barra, Fabio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g (2024) vom: 17. Apr., Seite 1-12 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:17 |g month:04 |g pages:1-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2024.2343786 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 17 |c 04 |h 1-12 | ||